Perspective Therapeutics, Inc.
CATX
$1.94
$0.094.87%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 234.00K | 369.00K | 526.00K | 325.00K | 337.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 234.00K | 369.00K | 526.00K | 325.00K | 337.00K |
| Cost of Revenue | 39.43M | -- | -- | -- | 20.34M |
| Gross Profit | -38.96M | 369.00K | 526.00K | 325.00K | -20.01M |
| SG&A Expenses | 8.25M | 6.98M | 5.51M | 5.88M | 4.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 15.00K |
| Total Operating Expenses | 21.13M | 19.00M | 14.79M | 13.33M | 12.04M |
| Operating Income | -20.90M | -18.63M | -14.26M | -13.01M | -11.70M |
| Income Before Tax | -42.21M | -15.12M | -11.28M | -11.82M | -11.64M |
| Income Tax Expenses | -2.10M | -- | -- | -- | 7.85M |
| Earnings from Continuing Operations | -40.11M | -15.12M | -11.28M | -11.82M | -19.49M |
| Earnings from Discontinued Operations | -59.00K | -- | -429.00K | -461.00K | -5.18M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.17M | -15.12M | -11.70M | -12.28M | -24.68M |
| EBIT | -20.90M | -18.63M | -14.26M | -13.01M | -11.70M |
| EBITDA | -40.38M | -17.97M | -13.69M | -12.65M | -11.46M |
| EPS Basic | -0.57 | -0.21 | -0.18 | -0.25 | -0.88 |
| Normalized Basic EPS | -0.16 | -0.13 | -0.11 | -0.15 | -0.26 |
| EPS Diluted | -1.14 | -0.21 | -0.18 | -0.25 | -0.88 |
| Normalized Diluted EPS | -0.16 | -0.13 | -0.11 | -0.15 | -0.26 |
| Average Basic Shares Outstanding | 70.82M | 70.63M | 66.65M | 49.51M | 28.09M |
| Average Diluted Shares Outstanding | 70.82M | 70.63M | 66.65M | 49.51M | 28.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |